Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
Status:
Completed
Trial end date:
2017-03-03
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving capecitabine together with lapatinib ditosylate may kill more
tumor cells.
PURPOSE: This phase II trial is studying how well giving capecitabine and lapatinib
ditosylate together works in treating patients with squamous cell cancer of the head and
neck.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania